Table 2.
Mortality and hospitalization by randomization in the SOLVD-Treatment trial, in all patients with data on baseline serum creatinine, and those with and without chronic kidney disease (CKD)
| % (events)
|
Absolute risk difference* (%) | HR (95% CI) | P value | ||
|---|---|---|---|---|---|
| Placebo | Enalapril | ||||
| Overall (N=2502) | n=1252 | n=1250 | |||
| All-cause mortality | 40% (502) | 35% (440) | – 5% | 0.84 (0.74–0.95) | 0.007 |
| CKD (n=1036) | n=538 | n=498 | |||
| Mortality | |||||
| All-cause | 45% (242) | 42% (207) | – 3% | 0.88 (0.73–1.06) | 0.164 |
| Cardiovascular | 40% (217) | 36% (177) | – 4% | 0.84 (0.69–1.02) | 0.079 |
| Progressive heart failure | 15% (80) | 15% (75) | 0% | 0.96 (0.70–1.31) | 0.792 |
| Arrhythmia without heart failure | 10% (54) | 9% (43) | – 1% | 0.82 (0.55–1.23) | 0.344 |
| Hospitalization | |||||
| All cause | 76% (408) | 73% (362) | – 3% | 0.83 (0.72–0.96) | 0.012 |
| Cardiovascular | 66% (353) | 59% (293) | – 7% | 0.77 (0.66–0.90) | 0.001 |
| Worsening heart failure | 39% (212) | 27% (134) | – 12% | 0.59 (0.48–0.73) | <0.001 |
| No CKD (n=1466) | n=714 | n=752 | |||
| Mortality | |||||
| All-cause | 36% (260) | 31% (233) | – 5% | 0.82 (0.69–0.98) | 0.028 |
| Cardiovascular | 33% (237) | 28% (211) | – 5% | 0.82 (0.68–0.98) | 0.031 |
| Progressive heart failure | 12% (85) | 10% (78) | – 2% | 0.84 (0.62–1.14) | 0.264 |
| Arrhythmia without heart failure | 9% (62) | 8% (60) | – 1% | 0.89 (0.62–1.27) | 0.522 |
| Hospitalization | |||||
| All cause | 74% (526) | 67% (505) | – 7% | 0.77 (0.69–0.88) | <0.001 |
| Cardiovascular | 62% (439) | 54% (408) | – 8% | 0.80 (0.70–0.91) | <0.001 |
| Worsening heart failure | 35% (246) | 26% (195) | – 9% | 0.68 (0.57–0.83) | <0.001 |
*
Absolute risk differences were estimated by subtracting event rates in the placebo group from those in the enalapril group